Stock EDIT EDITAS MEDICINE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Editas Medicine, Inc.

Equities

EDIT

US28106W1036

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
5.32 USD +1.92% Intraday chart for Editas Medicine, Inc. -3.10% -47.48%
03-13 Transcript : Editas Medicine, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 02:05 PM
02-29 Barclays Adjusts Price Target on Editas Medicine to $11 From $10, Maintains Equal-Weight Rating MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • One of the major weak points of the company is its financial situation.
  • Based on current prices, the company has particularly high valuation levels.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
EDITAS MEDICINE, INC. Stock Editas Medicine, Inc.
-47.48% 437M
C+
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
A
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
B-
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
C+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
B+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. EDIT Stock
  4. Ratings Editas Medicine, Inc.